BLUE * 주식 개요 는 미국에서 중증 유전 질환 치료를 위한 유전자 치료제를 연구, 개발 및 상용화하는 생명공학 회사입니다. 자세한 내용
보상 위험 분석 + 1 더 많은 위험
모든 위험 점검 보기 생각, 링크 및 회사 내러티브를 캡처하세요.
가격 내역 및 성능
다음에 대한 주가 최고가, 최저가 및 변동 요약 bluebird bio 과거 주가 현재 주가 US$186.96 52주 최고치 US$500.00 52주 최저치 US$180.00 베타 0.73 1개월 변경 -6.52% 3개월 변경 사항 -6.52% 1년 변경 사항 n/a 3년 변화 -95.55% 5년 변화 -99.33% IPO 이후 변화 -99.60%
최근 뉴스 및 업데이트
Insufficient new directors Dec 11 Bluebird Bio, Inc. Announces Updated Data from Patients with Beta-Thalassemia Who Require Regular Blood Transfusions Treated with Betibeglogene Autotemcel (Beti-Cel, Approved Commercially as ZYNTEGL) in Clinical Studies
Third quarter 2024 earnings released: US$0.31 loss per share (vs US$0.80 loss in 3Q 2023) Nov 16
New major risk - Revenue and earnings growth Nov 15
bluebird bio, Inc. to Present Additional Long-Term Follow-Up Data from Gene Therapy Programs in Sickle Cell Disease and Beta-Thalassemia at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition Nov 05
bluebird bio Receives Written Notice from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Requirement under Nasdaq Listing Rule 5450(a)(1) Oct 05 더 많은 업데이트 보기
Insufficient new directors Dec 11 Bluebird Bio, Inc. Announces Updated Data from Patients with Beta-Thalassemia Who Require Regular Blood Transfusions Treated with Betibeglogene Autotemcel (Beti-Cel, Approved Commercially as ZYNTEGL) in Clinical Studies
Third quarter 2024 earnings released: US$0.31 loss per share (vs US$0.80 loss in 3Q 2023) Nov 16
New major risk - Revenue and earnings growth Nov 15
bluebird bio, Inc. to Present Additional Long-Term Follow-Up Data from Gene Therapy Programs in Sickle Cell Disease and Beta-Thalassemia at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition Nov 05
bluebird bio Receives Written Notice from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Requirement under Nasdaq Listing Rule 5450(a)(1) Oct 05
bluebird bio, Inc., Annual General Meeting, Nov 06, 2024 Sep 19
bluebird bio Announces Receipt of Expected Notices from Nasdaq Due to Non-Compliance with Nasdaq Listing Rule 5250(c)(1) Aug 25 bluebird bio, Inc. Provides Revenue Guidance for the Third and Fourth Quarter of 2024
bluebird bio, Inc. Announces Chief Financial Officer Changes, Effective June 10, 2024 May 30 bluebird bio, Inc. announced delayed 10-Q filing May 17
Bluebird Bio, Inc. Announces Completion of First Cell Collection for LYFGENIA Gene Therapy May 07
Bragar Eagel & Squire, P.C. Files Class Action Lawsuit Against Bluebird Bio Inc Mar 29 bluebird bio, Inc. announced delayed annual 10-K filing Mar 27
Chief Medical Officer recently sold Mex$176k worth of stock Mar 10
Chief Medical Officer recently sold Mex$176k worth of stock Mar 08 bluebird bio, Inc. has completed a Follow-on Equity Offering in the amount of $125 million. Dec 21
bluebird bio, Inc. has completed a Follow-on Equity Offering in the amount of $125 million. Dec 20
bluebird bio, Inc. has filed a Follow-on Equity Offering in the amount of $150 million. Dec 19
Bluebird Bio Inc. Presents Long-Term Data At Ash Support Beti-Ccel as A Potentially Curative Gene Therapy for -Thalassemia Patients Who Require Regular Transfusion Independence and Normal or Near- Normal- Normal- Normal-Normal Adult Hb Levels Bluebird Bio Details Plans for the Commercial Launch of Lyfgenia(Tm) Gene Therapy for Patients Ages 12 and Older with Sickle Cell Disease and A History of Vaso-Occlusive Events
Bluebird Bio, Inc. to Present New and Updated Data from Gene Therapy Programs in Sickle Cell Disease and Beta-Thalassemia at the 65th American Society of Hematology Annual Meeting and Exposition Nov 03
bluebird bio, Inc. to Report Q3, 2023 Results on Nov 07, 2023 Oct 25
bluebird bio, Inc. Announces FDA Priority Review of the Biologics License Application for Lovotibeglogene Autotemcel (Lovo-Cel) for Patients with Sickle Cell Disease (Scd) 12 Years and Older with a History of Vaso-Occlusive Events Jun 22
Less than half of directors are independent Apr 12
Full year 2022 earnings released: US$3.39 loss per share (vs US$8.17 loss in FY 2021) Mar 31
Less than half of directors are independent Mar 30
Less than half of directors are independent Feb 17
bluebird bio, Inc. Appoints Joseph Vittiglio, JD as Chief Business and Legal Officer Jan 04
U.S. Food and Drug Administration Lifts Partial Clinical Hold for bluebird bio, Inc.’s Sickle Cell Disease Studies for Patients Under the Age of 18 Dec 20
Less than half of directors are independent Dec 16
Bluebird Bio, Inc. Presents New and Updated Data At the 64Th American Society of Hematology Annual Meeting and Exposition Dec 13
An unknown buyer entered into a definitive agreement to acquire SKYSONA & ZYNTEGLO of bluebird bio, Inc. (NasdaqGS:BLUE) for approximately $100 million. Dec 02 bluebird bio, Inc. Appoints Christopher Krawtschuk as Treasurer, Principal Financial Officer and Principal Accounting Officer
Less than half of directors are independent Oct 17 bluebird bio, Inc. Announces Executive Changes Effective October 14, 2022
bluebird bio Receives FDA Accelerated Approval for SKYSONA® Gene Therapy for Early, Active Cerebral Adrenoleukodystrophy (CALD) Sep 17 bluebird bio, Inc. Announces Executive Changes
Treasurer recently sold Mex$1.6m worth of stock Aug 25
bluebird bio, Inc. Announces FDA Approval of Zynteglo®, the First Gene Therapy for People with Beta-Thalassemia Who Require Regular Red Blood Cell Transfusions Aug 18
President recently sold Mex$1.9m worth of stock Aug 10
Second quarter 2022 earnings released: US$1.36 loss per share (vs US$2.31 loss in 2Q 2021) Aug 07
bluebird bio, Inc. Appoints Tom Klima as Chief Commercial & Operating Officer, Effective August 8, 2022 Aug 06
Chief Regulatory Officer recently sold Mex$140k worth of stock Jul 15
Less than half of directors are independent Jul 05
bluebird bio, Inc. Announces That the U.S. Food and Drug Administration's Cellular, Tissue and Gene Therapies Advisory Committee Recommends Approval of elivaldogene autotemcel (eli-cel) for the Treatment of Early Active Cerebral Adrenoleukodystrophy Jun 11
FDA Advisory Committee Unanimously Endorses eli-cel Gene Therapy for Cerebral Adrenoleukodystrophy Jun 10
Chief Commercial Officer recently sold Mex$226k worth of stock Jun 08
Less than half of directors are independent Jun 01
bluebird bio, Inc., Annual General Meeting, Jun 22, 2022 May 03 Bluebird Bio, Inc. Announces Executive Changes
bluebird bio, Inc. appoints Charlotte Jones-Burton as Class I director, effective March 7, 2022 Mar 06 bluebird bio, Inc. announced delayed annual 10-K filing Mar 03
Less than half of directors are independent Mar 01
bluebird bio, Inc. Announces Resignation of Jessica Whitten as Chief Accounting Officer and Principal Accounting Officer Feb 05
Less than half of directors are independent Feb 04
bluebird Provides Update on FDA Review Timelines for Betibeglogene Autotemcel (beti-cel) for Beta-Thalassemia and Elivaldogene Autotemcel (eli-cel) for Cerebral Adrenoleukodystrophy (CALD) Jan 19
Insider recently sold Mex$80k worth of stock Jan 15
bluebird bio, Inc. to Launch Both beti-cel and eli-cel for Patients in the U.S. in Mid-2022 Jan 12
Insider recently sold Mex$637k worth of stock Jan 08
Less than half of directors are independent Dec 29
bluebird bio, Inc. Announces Partial Clinical Hold for Patients Under 18 in Sickle Cell Gene Therapy Clinical Program Dec 21
bluebird bio Announces FDA Priority Review of Biologics License Application for eli-cel Gene Therapy for Cerebral Adrenoleukodystrophy (CALD) in Patients Without a Matched Sibling Donor Dec 19
CEO & Director recently sold Mex$179k worth of stock Dec 14
bluebird bio, Inc. Announces Updated Results from its Phase 1/2 HGB-206 Study of Lovotibeglogene Autotemcel Gene Therapy Dec 13
New Data At ASH21, Published in Nejm Further Demonstrate Beti-Cel as A Potentially Curative One-Time Gene Therapy for ß-Thalassemia Patients Who Require Regular Transfusions Through Achievement of Durable Ti and Normal or Near-Normal Adult Hb Levels Dec 12
Independent Director Wendy Dixon has left the company Nov 29
Independent Director Wendy Dixon has left the company Nov 29
Independent Director Wendy Dixon has left the company Nov 29
Independent Director Wendy Dixon has left the company Nov 29
Independent Director Wendy Dixon has left the company Nov 28
Independent Director Wendy Dixon has left the company Nov 28
Independent Director Wendy Dixon has left the company Nov 28
Independent Director Wendy Dixon has left the company Nov 28
Independent Director Wendy Dixon has left the company Nov 28
Independent Director Wendy Dixon has left the company Nov 28
Independent Director Wendy Dixon has left the company Nov 28
Independent Director Wendy Dixon has left the company Nov 28
Independent Director Wendy Dixon has left the company Nov 28
Independent Director Wendy Dixon has left the company Nov 28
Independent Director Wendy Dixon has left the company Nov 28 주주 수익률 BLUE * MX Biotechs MX 마켓 7D 0% 0% 0% 1Y n/a 0% 0%
전체 주주 수익률 보기
수익률 대 산업: MX Biotechs 산업에 대해 BLUE * 의 성과를 판단하기에는 데이터가 부족합니다.
수익률 대 시장: MX 시장에 대해 BLUE * 의 성과를 판단하기에는 데이터가 부족합니다.
가격 변동성 Is BLUE *'s price volatile compared to industry and market? BLUE * volatility BLUE * Average Weekly Movement n/a Biotechs Industry Average Movement 0% Market Average Movement 0% 10% most volatile stocks in MX Market 0% 10% least volatile stocks in MX Market 0%
안정적인 주가: BLUE * 의 주가는 지난 3개월 동안 MX 시장과 비교해 변동성이 컸습니다.
시간에 따른 변동성: 지난 1년간 BLUE * 의 변동성 변화를 확인하기에는 데이터가 충분하지 않습니다 .
회사 소개 는 미국에서 중증 유전 질환 치료를 위한 유전자 치료제를 연구, 개발 및 상용화하는 생명공학 회사입니다. 이 회사의 중증 유전 질환 치료 제품 후보로는 수혈 의존성 지중해빈혈 치료제 진테글로(ZYNTEGLO, 베티베글로겐 오토템셀), 겸상 적혈구 질환(SCD) 치료제 로보티베글로겐 오토템셀, 뇌부신백질이영양증 치료제 스카이소나(스카이소나 엘리발도진 오토템셀) 등이 있습니다. 임상 개발 프로그램에는 SCD 환자 치료에서 로보셀의 안전성과 효능을 평가하기 위한 HGB-205, HGB-206 및 HGB-210과 지중해빈혈 환자 치료에서 베티셀의 안전성과 효능을 평가하기 위한 HGB-204, HGB-205, HGB-207 및 HGB-212가 있습니다.
자세히 보기 bluebird bio, Inc. 기본 사항 요약 bluebird bio 의 수익과 매출은 시가총액과 어떻게 비교하나요? BLUE * 기본 통계 시가총액 Mex$1.84b 수익(TTM ) -Mex$6.05b 수익(TTM ) Mex$1.10b
수익 및 수익 최신 수익 보고서의 주요 수익성 통계(TTM) BLUE * 손익 계산서(TTM ) 수익 US$53.12m 수익 비용 US$78.78m 총 이익 -US$25.66m 기타 비용 US$267.16m 수익 -US$292.82m
주당 순이익(EPS) -30.12 총 마진 -48.31% 순이익 마진 -551.25% 부채/자본 비율 -1,394.4%
BLUE * 의 장기적인 성과는 어땠나요?
과거 실적 및 비교 보기
기업 분석 및 재무 데이터 현황 데이터 마지막 업데이트(UTC 시간) 기업 분석 2025/01/05 05:52 장 마감 주가 2024/12/19 00:00 수익 2024/09/30 연간 수익 2023/12/31
데이터 소스 기업 분석에 사용된 데이터는 S&P Global Market Intelligence LLC의 데이터입니다. 이 보고서를 생성하기 위해 분석 모델에 사용된 데이터는 다음과 같습니다. 데이터는 정규화되어 있으므로 소스가 제공되기까지 지연이 발생할 수 있습니다.
패키지 데이터 기간 미국 소스 예시 * 회사 재무 10년 애널리스트 컨센서스 추정치 +3년 시장 가격 30년 소유권 10년 관리 10년 주요 개발 사항 10년
* 미국 증권의 경우, 미국 외 지역의 규제 양식 및 출처가 사용된 예입니다.
명시되지 않는 한 모든 재무 데이터는 1년을 기준으로 하지만 분기별로 업데이트됩니다. 이를 후행 12개월(TTM) 또는 최근 12개월(LTM) 데이터라고 합니다. 여기에서 자세히 알아보세요.
분석 모델 및 눈송이 이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 Github 페이지에서 확인할 수 있으며, 보고서 사용 방법에 대한 가이드와 튜토리얼도 유튜브에서 확인할 수 있습니다.
Simply 월스트리트 분석 모델을 설계하고 구축한 세계적인 수준의 팀에 대해 알아보세요.
산업 및 부문 메트릭 업계 및 섹션 지표는 Simply Wall St에서 6시간마다 계산되며, 자세한 내용은 확인할 수 있습니다.
애널리스트 출처 bluebird bio, Inc. 33 애널리스트 중 9 애널리스트가 보고서의 입력 자료로 사용된 매출 또는 수익 추정치를 제출했습니다. 애널리스트의 제출 자료는 하루 종일 업데이트됩니다.
분석가 교육기관 Jack Allen Baird Huidong Wang Barclays Zhiqiang Shu Berenberg
30 더 많은 분석가 보기 
